Selank vs. Dihexa for Cognitive Recovery in Veterans with AUD: A Nootropic Comparison
Veterans with alcohol use disorder often face lasting cognitive deficits. Two research peptides, Selank and Dihexa, are discussed as potential nootropics for recovery. But the evidence base for each is thin, and no head-to-head trial exists.
Why Compare These Two Compounds?
Alcohol use disorder (AUD) damages the brain. Veterans, in particular, show high rates of AUD and related cognitive impairment. The VA is currently running a trial on semaglutide (a GLP-1 agonist) for AUD. That trial focuses on drinking reduction, not cognitive repair. This leaves a gap. Researchers are looking at peptides that might directly improve cognition after alcohol-related damage. Selank and Dihexa represent two distinct approaches. Selank is an anxiolytic with nootropic claims. Dihexa is a neurotrophic agent. Comparing them highlights the state of the science. It also reveals where evidence is missing.
Selank: Anxiolytic with Cognitive Claims
Selank is a synthetic heptapeptide. It is an analogue of tuftsin. It was developed in Russia. Its primary mechanism is modulation of GABA and monoamine systems. A 2018 review (PubMed) describes Selank as having anxiolytic and nootropic effects. The idea is that reducing anxiety may indirectly improve cognition. Some rodent studies suggest direct neuroprotective effects. A 2019 study (PubMed) reported Selank improved memory in rats with chronic alcohol intoxication. This is a 2 of 5 on evidence quality. It is one small animal study. No human trial has tested Selank for alcohol-related cognitive recovery. The compound is not FDA-approved. It is sold as a research chemical. Our internal piece on Selank and anxiety-induced cognitive fog notes similar limitations. Any cognitive benefit in humans is speculative.
Dihexa: Potent Neurotrophic with High Risk
Dihexa is a small molecule. It is a derivative of angiotensin IV. It binds hepatocyte growth factor (HGF) and potentiates its activity at the c-Met receptor. This promotes synaptic growth. A 2012 study (PubMed) showed Dihexa improved cognitive performance in scopolamine-impaired rats. That is a 1 of 5 on evidence quality for AUD. No study has tested Dihexa in an alcohol model. The compound is extremely potent. It crosses the blood-brain barrier. There are no human trials. Safety data are absent. A related article on P21 and Dihexa stack for TBI recovery underscores the lack of human data. Dihexa's mechanism suggests it could theoretically repair alcohol-induced synaptic loss. But this is pure conjecture. The risk of uncontrolled cell growth is a major concern.
Head-to-Head Evidence: Nonexistent
There is no study comparing Selank and Dihexa. Not in animals. Not in humans. The question "which is better for cognitive recovery in veterans with AUD?" has no direct answer. We can only compare mechanisms and indirect evidence. Selank has one rodent study in an alcohol model. Dihexa has zero. Selank has a longer history of human use in Russia for anxiety. Dihexa has never been in humans. The VA's GLP-1 trial does not involve either peptide. It is a red herring in this comparison. The trial highlights the need for cognitive endpoints in AUD research. But it provides no data on nootropics.
Where Each Is Studied More
Selank is studied primarily in Russia. Research focuses on anxiety and stress. Some work explores cognitive enhancement in healthy subjects. A 2020 study (PubMed) found Selank improved attention in healthy volunteers. That is a 2 of 5 on evidence quality. It was a small, open-label trial. Dihexa is studied in academic labs in the US. The focus is on neurodegenerative disease. A 2014 study (PubMed) showed Dihexa restored cognitive function in a rat model of Alzheimer's. That is irrelevant to AUD. Another internal post on P21 and Pinealon stack discusses related cognitive peptides. None have AUD-specific data. The bottom line: Selank has slightly more relevant animal data. Dihexa has a more compelling mechanism but far greater unknowns. Neither is ready for clinical use.
This article discusses peptides as research compounds. It is not medical advice.